Ana María Hunt submitted her story about how she went from near-death to life, thanks to oral vancomycin. Ana María, a 52-year old PSC patient, had been living with liver cirrhosis.
In addition, she’d been experiencing debilitating symptoms including brain fog and chronic fatigue. Because of this, she’d had to stop working.
Then, she started taking oral vancomycin. After just three months of 1,500 mg per day, her health took a 180-degree turn! Below, Ana María shares her incredible story—and a plea for the healthcare community.
Patient Story: Submitted by Ana María Hunt
Everything improved! I have more energy, less brain fog, my quality of life has increased, and my gut has never been better. I hadn’t been able to work, but now I’m ready to go back to work after only three months on oral vancomycin!
My friends and family say I have “life” back in my face. I literally felt as I was nearing death, until I started oral vancomycin.
Before vancomycin, I suffered. All I keep thinking is why would the healthcare community make us suffer? Please don’t make us suffer anymore. I can’t imagine going back to death.
Additional Resources
Unfortunately, oral vancomycin for PSC can be very to access. To learn more about the background behind An María’ Hunt’s plea to the healthcare community, read this blog post about the American Association for the Study of Liver Diseases (AASLD) Guidance and how it’s impacting PSC patient’s insurance coverage.
This is exactly why patient stories are POWRFUL. Words have the power to change. We need your stories to show the AASLD, and the healthcare community as a whole, the hope that oral vancomycin brings to the PSC community.
Want to Share Your Vancomycin Story?
Stories drive change. They tug on heartstrings and connect us as humans. If we want to drive change and make vancomycin more accessible to the PSC community, we need to share our stories. Share your vancomycin story by filling out this Google form ASAP!
Share your vancomycin story.
Be featured on this page.
Help drive change.
Leave a Reply